Vol. 6, Issue 4, Part F (2020)
Antibacterial effect of amorphous calcium phosphate-casein phosphopeptide varnish against Streptococcus mutans: An exploratory in vivo randomized controlled trial
Author(s):
Denzy Lawrence and Puja C Yavagal
Abstract:
Background: Nowadays, amorphous calcium phosphate-casein phosphopeptide and tricalcium phosphate are being incorporated into fluoride varnishes to enhance remineralization potential which might interfere with antibacterial effect of fluoride in varnishes. Aim of study was to evaluate and compare the antimicrobial property of sodium fluoride varnish reinforced with amorphous calcium phosphate-casein phosphopeptide and tricalcium phosphate against streptococcus mutans.
Methods: In the clinical setting, trial was conducted involving 18, 14-15 year old school children, randomly allocated into three interventional groups, Group A (5% Sodium fluoride varnish, Fluoritop-SR varnish), Group B (5% Sodium fluoride - Tricalcium phosphate varnish, Clinpro White varnish) and Group C (5% Sodium fluoride- amorphous calcium phosphate-casein phosphopeptide varnish, MI Varnish) to receive the varnish application. Saliva samples were collected at the end of one hour after varnish application for S Mutans count estimation. Student’s paired ‘t’ test and One way-ANOVA tests were used for statistical analyses.
Results: Significant reductions in salivary streptococcus mutans count at one hour was achieved with application of B & C varnishes compared to varnish A.
Conclusion: amorphous calcium phosphate-casein phosphopeptide and tricalcium phosphate varnish groups exhibited better antimicrobial property against streptococcus mutans compared to Sodium fluoride varnish at one-hour post intervention.
Pages: 389-391 | 1358 Views 327 Downloads
How to cite this article:
Denzy Lawrence and Puja C Yavagal. Antibacterial effect of amorphous calcium phosphate-casein phosphopeptide varnish against Streptococcus mutans: An exploratory in vivo randomized controlled trial. Int. J. Appl. Dent. Sci. 2020;6(4):389-391. DOI: 10.22271/oral.2020.v6.i4f.1093
